Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Affymax has reached $5m development milestone payment in the exclusive global agreement with Takeda Pharmaceutical Company to develop and commercialize peginesatide.
Subscribe to our email newsletter
The European Medicines Agency’s (EMA) acceptance of the marketing authorization application (MAA) of peginesatide has triggered the milestone.
Peginesatide, indicated to treat anemia associated with chronic kidney disease (CKD) in adult patients on dialysis, was discovered by Affymax.
If approved, peginesatide will be co-marketed by Affymax and Takeda in the US. Takeda has commercialization rights in the European Union.
Affymax president and CEO John Orwin said the company is encouraged by the EMA acceptance of the MAA.
"While we are concurrently preparing for potential commercialization of peginesatide in the United States, we are pleased that progress is being made to potentially make the product available outside the US," Orwin added.